The BLimfoPred project, led by Atrys and with the collaboration of IDIPHISA, receives support from the State Research Agency to improve the diagnosis and treatment of an aggressive type of B lymphoma

Atrys Health, a global healthtech company that provides prevention, diagnosis and precision medical treatment services, leader in telemedicine and oncology treatment, will lead the BLinfoPred project, focused on the development of advanced technologies to improve the diagnosis and treatment of Lymphoma B Diffuse Large Cell Lymphoma (LBDCG), an aggressive type of lymphoma.

BLinfoPred is an initiative resulting from a consortium between our company and the Lymphoma Research Group of the Instituto de Investigación Sanitaria Puerta de Hierro – Segovia de Arana (IDIPHISA), attached to the Medical Oncology Department of the Hospital Universitario Puerta de Hierro Majadahonda. This consortium has just received financial support in the call for grants for public-private collaboration projects of the State Plan for Scientific, Technical and Innovation Research 2021-2023.

LBDCG is a complex and aggressive lymphoma that responds favorably to standard treatment with immunochemotherapy (R-CHOP) in approximately 70% of cases. However, in the remaining patients it shows resistance or relapses, which complicates its clinical management. Currently, there are no reliable tools to accurately predict the response to treatment. Therefore, through BLinfoPred, Atrys and the Lymphoma Research Group of the Instituto de Investigación Sanitaria Puerta de Hierro – Segovia de Arana, seek to develop and validate predictive tools based on omics technology and liquid biopsy, which allow an accurate genetic classification of LBDCG and the prediction of therapeutic response.

As Dr. Margarita Sánchez-Beato, head of IDIPHISA’s Lymphoma Research Group, points out, “the BLinfoPred project represents a key advance in the personalization of the treatment of Diffuse Large Cell Lymphoma B. Through the creation of a new cohorts, the BLinfoPred project will be able to identify and validate the most appropriate treatment for LBDCG. Through the creation of a cohort of patients and genomic characterization by liquid biopsy, we seek to accurately classify lymphoma and predict response to treatment. In addition, the development of artificial intelligence models and a validated clinical kit will allow us to identify patients at higher risk and improve their clinical management, offering access to personalized treatments,” he said.

For his part, Dr. José Antonio López, medical director of the Precision Medicine area at Atrys, emphasizes that the development of this type of project is necessary to contribute to improving the treatment of Diffuse Large Cell Lymphoma B and to broaden access to advanced predictive tools in personalized oncology. “These advances make it possible to develop more precise and effective therapies for patients, adapted to the molecular characteristics of their disease,” he said.

In addition to the participation of Atrys and IDIPHISA’s Lymphoma Research Group, the BLinfoPred consortium has the support of the Oncology Group for the Treatment and Study of Lymphomas (GOTEL), which collaborates in the recruitment of patients and the collection of clinical data and biological samples.